SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 2008--Illumina, Inc. (NASDAQ:ILMN) today announced that the Company was added to the NASDAQ-100 Index(R), effective at the start of trading Monday, December 15, 2008.
The NASDAQ-100 Index is comprised of the 100 largest non-financial stocks on The NASDAQ Stock Market(R) based on market capitalization. Illumina shares will also be added to the PowerShares QQQ Trust (NasdaqGM:QQQQ) which aims to provide investment results that, before expenses, correspond with the NASDAQ-100 Index Performance.
"We are delighted to be added to the NASDAQ-100 Index," said Jay T. Flatley, President and Chief Executive Officer of Illumina. "Being included in of one of the most visible global indices is an important milestone for Illumina, and a testament to the hard work and dedication of our employees since Illumina was founded 10 years ago."
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
CONTACT: Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Maurissa Bornstein
Public Relations Manager
858-332-4055
mbornstein@illumina.com
Source: Illumina, Inc.